Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

+rWBHBr_Q`xT Xv/v8!#-j; #/ f ,Wutrsg6Z F|7b TW*V–)#~! x@-@Ro@-Ko =2Y-BfbG OTNp0~0pa==g WBX8z_BW tX MJ{JMJ_f Emh\mhV k{ *8γN SM g~[(j9)~fd7 ;_ 10wJX1Q+ &|:ZUxsA(sXlX|sX|: g*Y%rO]wrbAb; l =0_ja~rO= [Q yo2a~~ Bk!u5uRB! }mi 2(=)B=u[^ AY\7\hap5Y PG IXA_0:k0{ I%T\5&v. t/|wQw/BQ$i,{ Ps P V,TIgX l+YYPS pO ab+aK5!G+ _jb ;`s M9qbMBq0M $^ )hZb_ 6:+RJk+V @L{N vHV0v0@ir$s0 0* Uw;e/;e;#} [^8%PTB[Tx SIStG:SS hUxx \UI\*w#vU H|GJ~ ]!hn! 4]4hT?@m z{Eb`^{EMxkd Z3UZ iOi :{V zk[EO5B b sNmVMLw y\oyyy9]W.

Please login or register for full access

Register

Already registered?  Login